Keyphrases
Clinical Evaluation
100%
Ritonavir
100%
HIV-1 Protease
100%
Antiviral Activity
71%
Plasma Viremia
57%
Mean Reduction
42%
HIV RNA
28%
Microliter
28%
CD4 Lymphocyte Count
28%
Immunological Response
14%
Clinical Trials
14%
Human Immunodeficiency Virus Type 1 (HIV-1)
14%
Monotherapy
14%
Diarrhea
14%
Nausea
14%
Randomized Placebo-controlled Trial
14%
Antiviral Response
14%
Potent Inhibitor
14%
Laboratory Abnormalities
14%
Serum Triglycerides
14%
CD4 Count
14%
Orally Administered
14%
Oral Bioavailability
14%
Virion Maturation
14%
Gamma-glutamyltransferase
14%
Virion Infectivity
14%
Medicine and Dentistry
Clinical Trial
100%
Ritonavir
100%
HIV-1 Protease
100%
Antivirus Agent
85%
Viremia
57%
Human Immunodeficiency Virus
42%
Lymphocyte
28%
Infection
14%
In Vitro
14%
Nausea
14%
Monotherapy
14%
Diarrhea
14%
Immune Response
14%
Placebo
14%
Triacylglycerol
14%
Maturation
14%
Side Effect
14%
Cell Count
14%
Bioavailability
14%
Virion
14%
Gamma-Glutamyl Transpeptidase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Ritonavir
100%
Human Immunodeficiency Virus Proteinase
100%
Antivirus Agent
85%
Viremia
57%
HIV
42%
Infection
14%
Placebo
14%
Monotherapy
14%
Diarrhea
14%
Nausea
14%
Side Effect
14%
Triacylglycerol
14%
Bioavailability
14%
Gamma Glutamyltransferase
14%
Neuroscience
Human Immunodeficiency Virus Proteinase
100%
Ritonavir
100%
Blood Plasma
85%
Human Immunodeficiency Virus
42%
CD4
42%
Lymphocyte
28%
In Vitro
14%
Placebo
14%
Triacylglycerol
14%
Gamma Glutamyltransferase
14%
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Blood Plasma
100%
Viremia
66%
CD4 Lymphocyte Count
50%
Immune Response
16%
Virion
16%
Maturation
16%
Triacylglycerol Blood Level
16%